• Publications
  • Influence
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
Huntington's disease (HD) is an inherited, progressive neurological disorder that is caused by a CAG/polyglutamine repeat expansion and for which there is no effective therapy. Recent evidenceExpand
  • 790
  • 32
  • PDF
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
Huntington's Disease (HD) is an inherited neurological disorder causing movement impairment, personality changes, dementia, and premature death, for which there is currently no effective therapy. TheExpand
  • 158
  • 9
Standardization and statistical approaches to therapeutic trials in the R6/2 mouse
The R6/2 mouse is the most widely used animal model of Huntington's disease (HD), a genetic disorder causing movement disorders, personality changes, dementia, and premature death, for which there isExpand
  • 134
  • 9
Environmental enrichment slows disease progression in R6/2 Huntington's disease mice
Huntington's disease is a genetic disorder that causes motor dysfunction, personality changes, dementia, and premature death. There is currently no effective therapy. Several transgenic models ofExpand
  • 235
  • 6
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease.
In postmortem Huntington's disease brains, mutant htt is present in both nuclear and cytoplasmic compartments. To dissect the impact of nuclear and extranuclear mutant htt on the initiation andExpand
  • 105
  • 5
  • PDF
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormalExpand
  • 62
  • 3
Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles
Huntington's disease (HD) is a late onset neurodegenerative disorder caused by a CAG/polyglutamine (polyQ) repeat expansion. PolyQ aggregates can be detected in the nuclei and processes of neurons inExpand
  • 77
  • 2
  • PDF
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Purpose of review Research conducted over the past 10 years has uncovered molecular mechanisms that are likely to be important in the early stages of Huntington's disease pathogenesis. This reviewExpand
  • 58
Plans for HDBase—a research community website for Huntington's Disease
Abstract We are developing a community website, called HDBase, to support basic scientific research on Huntington's Disease (HD). The core of the site is expert-reviewed scientific content consistingExpand
  • 4
Chapter 14 - Molecular Pathogenesis and Therapeutic Targets in Huntington's Disease
This chapter discusses molecular pathogenesis and therapeutic targets in Huntington's disease (HD). HD is an autosomal dominant, late onset neurodegenerative disease that is caused by aExpand
  • 2